4-methylamino-alpha,2-dimethylphenethylamine: structure given in first source; RN given refers to (+)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 133230 |
| MeSH ID | M0106735 |
| Synonym |
|---|
| 79567-43-4 |
| benzeneethanamine, alpha,2-dimethyl-4-(methylamino)-, (s)- |
| 4-methylamino-alpha,2-dimethylphenethylamine |
| fla-788 |
| fla 788 |
| 4-[(2s)-2-aminopropyl]-n,3-dimethylaniline |
| 4-(2-aminopropyl)-n,3-dimethylaniline |
| DTXSID901000597 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " During dosing with amiflamine or placebo, no subject tolerated 400 mg oral tyramine and no difference between the two regimens was found with regard to tyramine response." | ( Pressor response of oral tyramine in healthy men given amiflamine and placebo. Alván, G; Graffner, C; Grind, M; Gustafsson, LL; Helleday, J; Lindgren, JE; Ogenstad, S; Selander, H; Siwers, B, 1986) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||